Corvus Pharmaceuticals, Inc.
News
Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma
Globe Newswire Soquelitinib is a potential first-in-class ITK inhibitor with broad potential in cancer and immune diseases There are currently no fully approved agents for the treatment of relapsed PTCL and...\n more…
Corvus Pharmaceuticals (NASDAQ:CRVS) Downgraded to Sell at StockNews.com
Ticker Report StockNews.com cut shares of Corvus Pharmaceuticals (NASDAQ:CRVS - Free Report) from a hold rating to a sell rating in a research report released on Thursday morning. Corvus Pharmaceuticals Trading...\n more…
Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Globe Newswire BURLINGAME, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D...\n more…
Retail investors among Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) largest shareholders, saw gain in holdings value after stock jumped 10% last week
Simply Wall St Key Insights Significant control over Corvus Pharmaceuticals by retail investors implies that the general public has...\n more…
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Sees Significant Drop in Short Interest
Ticker Report Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) saw a large drop in short interest during the month of July. As of July 31st, there was short interest totalling 1,150,000 shares, a drop...\n more…
Corvus Pharmaceuticals, Inc. 2024 Q2 - Results - Earnings Call Presentation
SeekingAlpha Corvus Pharmaceuticals, Inc. 2024 Q2 - Results - Earnings Call Presentation...\n more…